CLINICAL TRIALS ARTICLES
-
"Raiders Of The Lost Codon:" Alltrna On Evolving "Ancient" tRNA Into Therapeutics
Here, in part one of this two-part article, we identify how tRNA stands apart from other RNA modalities and gene therapies, as well as how this molecule’s unique “skill set” is guiding the company’s future clinical strategy.
-
Learning From Oligos: Delivery & Clinical Strategies For mRNA Therapeutics
Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology.
-
Cultivating A Thriving mRNA Ecosystem: Key Initiatives & Future Directions
Overall, I felt that the following initiatives/talking points were demonstrative of the types of creativity and symbiosis that we will need much more of in the near and long-term to foster a healthy and fruitful RNA ecosystem.
-
From Promise To Precision: Defining The Therapeutic Niche for mRNA
CureVac CEO Alexander Zehnder shares his thoughts/visions on how mRNA neoantigen vaccines could become even more revolutionary for patient populations in the future. Though it may be early days, this conversation is a great case study for how RNA companies are striving to keep both scientific and commercial market opportunities top of mind from the earliest days of development.
-
The Marriage of Science & Strategy: Identifying mRNA Therapeutics' Value Propositions
Though it’s not a question we can answer fully yet, in the first of this two-part article, CureVac CEO Alexander Zehnder starts us down the path of answering a critical question about our RNA therapies: In what ways can and should our mRNA products add value to our patients’ lives?
-
Top 5 mRNA/RNA Developments of 2024 (Part 1)
In the past few weeks, I’ve shared two articles outlining several RNA executives’ thoughts on advancements from 2024, as well as the challenges facing us in 2025. But why stop there? Below in the first of this two-part article, I share the first two of my five overarching observations from 2024.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Explore the growing number of clinical trials and innovative approaches for Idiopathic Pulmonary Fibrosis (IPF) treatments.
-
The global infectious disease clinical trial landscape has rapidly expanded between 2020 and 2024, driven by the urgency of emerging threats, technological innovation, and evolving regulatory frameworks.
-
This report analyzes the current state of global and Asia-Pacific obesity trials, highlighting regional trends, sponsor activity, and preferred endpoints.
-
Explore this comprehensive overview of patient recruitment in clinical trials, emphasizing its critical role in ensuring diverse and representative participant pools essential for credible research outcomes.
-
In the rapidly evolving landscape of drug development, Contract Research Organizations (CROs) play a pivotal role. Learn more about CRO and selecting the right one to partner with.
-
What are clinical trials and how do they typically unfold? In this Q&A, you will learn about the four distinct clinical trial phases, participation eligibility, recruitment and more.
-
Australia's clinical landscape presents a compelling environment for early-phase clinical trials, characterized by regulatory efficiency and cost-effectiveness.